Literature DB >> 17941842

A combination of ketamine and diazepam synergistically controls refractory status epilepticus induced by cholinergic stimulation.

Brandon S Martin1, Jaideep Kapur.   

Abstract

PURPOSE: New treatments are needed for status epilepticus (SE) that is refractory to drugs modulating GABA(A) receptors, and NMDA receptor antagonists are candidate drugs.
METHODS: Clinically available NMDA receptor antagonist ketamine was tested for effectiveness in terminating prolonged SE induced by a combination of lithium and pilocarpine. Animals were treated 10 min after first grade 5 behavioral seizure (Racine scoring scale) by intraperitoneal administration of ketamine, diazepam, or saline. Seizure termination was determined by electroencephalogram (EEG) recordings from the hippocampus and the cortex.
RESULTS: Animals treated with normal saline or either 20 mg/kg diazepam, or 50 mg/kg ketamine continued in SE for the next 300 min. However, combined treatment with diazepam and ketamine rapidly terminated prolonged cholinergic stimulation-induced SE. Detailed study of dose response relationships demonstrated that diazepam enhanced efficacy and potency of ketamine in terminating SE. DISCUSSION: This study demonstrated synergistic action of diazepam and ketamine in terminating SE. It suggests that a ketamine-diazepam combination might be a clinically useful therapeutic option for the treatment of refractory SE.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17941842      PMCID: PMC2844443          DOI: 10.1111/j.1528-1167.2007.01384.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  42 in total

1.  Protein kinase C modulates NMDA receptor trafficking and gating.

Authors:  J Y Lan ; V A Skeberdis; T Jover; S Y Grooms; Y Lin; R C Araneda; X Zheng; M V Bennett; R S Zukin
Journal:  Nat Neurosci       Date:  2001-04       Impact factor: 24.884

Review 2.  Modulation of GABAA receptor activity by phosphorylation and receptor trafficking: implications for the efficacy of synaptic inhibition.

Authors:  Josef T Kittler; Stephen J Moss
Journal:  Curr Opin Neurobiol       Date:  2003-06       Impact factor: 6.627

3.  A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus.

Authors:  B K Alldredge; A M Gelb; S M Isaacs; M D Corry; F Allen; S Ulrich; M D Gottwald; N O'Neil; J M Neuhaus; M R Segal; D H Lowenstein
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

4.  Phenobarbital and MK-801, but not phenytoin, improve the long-term outcome of status epilepticus.

Authors:  Avinash Prasad; John M Williamson; Edward H Bertram
Journal:  Ann Neurol       Date:  2002-02       Impact factor: 10.422

5.  Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity.

Authors:  Eroboghene E Ubogu; Stephen M Sagar; Alan J Lerner; Brian N Maddux; José I Suarez; Mary Ann Werz
Journal:  Epilepsy Behav       Date:  2003-02       Impact factor: 2.937

6.  Characterization of pharmacoresistance to benzodiazepines in the rat Li-pilocarpine model of status epilepticus.

Authors:  Dorothy M Jones; Nadia Esmaeil; Stephen Maren; Robert L Macdonald
Journal:  Epilepsy Res       Date:  2002-08       Impact factor: 3.045

7.  Brain-derived neurotrophic factor modulates fast synaptic inhibition by regulating GABA(A) receptor phosphorylation, activity, and cell-surface stability.

Authors:  Jasmina N Jovanovic; Philip Thomas; Josef T Kittler; Trevor G Smart; Stephen J Moss
Journal:  J Neurosci       Date:  2004-01-14       Impact factor: 6.167

8.  A comparison of three NMDA receptor antagonists in the treatment of prolonged status epilepticus.

Authors:  Weiwei Yen; John Williamson; Edward H Bertram; Jaideep Kapur
Journal:  Epilepsy Res       Date:  2004-03       Impact factor: 3.045

9.  Oral ketamine in paediatric non-convulsive status epilepticus.

Authors:  L D Mewasingh; T Sékhara; A Aeby; F J C Christiaens; B Dan
Journal:  Seizure       Date:  2003-10       Impact factor: 3.184

Review 10.  The potential role of ketamine in hospice analgesia: a literature review.

Authors:  Justin Legge; Nicholas Ball; David P Elliott
Journal:  Consult Pharm       Date:  2006-01
View more
  48 in total

1.  Susceptibility to Soman Toxicity and Efficacy of LY293558 Against Soman-Induced Seizures and Neuropathology in 10-Month-Old Male Rats.

Authors:  James P Apland; Vassiliki Aroniadou-Anderjaska; Taiza H Figueiredo; Eric M Prager; Cara H Olsen; Maria F M Braga
Journal:  Neurotox Res       Date:  2017-08-03       Impact factor: 3.911

Review 2.  Management of refractory status epilepticus in adults: still more questions than answers.

Authors:  Andrea O Rossetti; Daniel H Lowenstein
Journal:  Lancet Neurol       Date:  2011-10       Impact factor: 44.182

Review 3.  Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research.

Authors:  Wolfgang Löscher; Claudia Brandt
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

4.  Combined diazepam and MK-801 therapy provides synergistic protection from tetramethylenedisulfotetramine-induced tonic-clonic seizures and lethality in mice.

Authors:  Michael P Shakarjian; Mahil S Ali; Jana Velíšková; Patric K Stanton; Diane E Heck; Libor Velíšek
Journal:  Neurotoxicology       Date:  2015-03-14       Impact factor: 4.294

5.  Ketamine for Refractory Status Epilepticus: A Systematic Review.

Authors:  Anna Rosati; Salvatore De Masi; Renzo Guerrini
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749

6.  Endogenous neurosteroid synthesis modulates seizure frequency.

Authors:  Courtney Lawrence; Brandon Scott Martin; Chengsan Sun; John Williamson; Jaideep Kapur
Journal:  Ann Neurol       Date:  2010-05       Impact factor: 10.422

7.  Dynamics of interictal spikes and high-frequency oscillations during epileptogenesis in temporal lobe epilepsy.

Authors:  Pariya Salami; Maxime Lévesque; Ruba Benini; Charles Behr; Jean Gotman; Massimo Avoli
Journal:  Neurobiol Dis       Date:  2014-03-28       Impact factor: 5.996

Review 8.  Animal models of temporal lobe epilepsy following systemic chemoconvulsant administration.

Authors:  Maxime Lévesque; Massimo Avoli; Christophe Bernard
Journal:  J Neurosci Methods       Date:  2015-03-10       Impact factor: 2.390

9.  N-methyl-D-aspartic acid receptor activation downregulates expression of δ subunit-containing GABAA receptors in cultured hippocampal neurons.

Authors:  Suchitra Joshi; Jaideep Kapur
Journal:  Mol Pharmacol       Date:  2013-04-12       Impact factor: 4.436

10.  Somatostatin type-2 receptor activation inhibits glutamate release and prevents status epilepticus.

Authors:  Maxim Kozhemyakin; Karthik Rajasekaran; Marko S Todorovic; Samuel L Kowalski; Corinne Balint; Jaideep Kapur
Journal:  Neurobiol Dis       Date:  2013-03-05       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.